Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 12, 2011

View Archived Issues

Trophos discloses new first-in-human data on TRO-40303

U.S. government contracts Elusys to develop anthrax antitoxin for pre- and postexposure prophylaxis

Korean University links putative oncogene to development of hepatocellular carcinoma

Genentech discloses new brain-penetrant PI3K inhibitors

Long-term safety of alipogene tiparvovec evaluated in patients with lipoprotein lipase deficiency

Phase Ia trial assesses CPG-7909-adjuvanted BioThrax

GlaxoSmithKline patents novel therapeutics for hepatitis C

New inhibitors of Sn1-specific diacylglycerol lipases reported

TransTech Pharma claims new RAGE antagonists

Novel IL-1 beta inhibitors disclosed by Ampla Pharmaceuticals

Affitech generates new antibodies against chemokine CXCR4 receptor

First triptan for migraine in adolescents approved in Canada

Two new companies spun out of Amira Pharmaceuticals

European Commission grants orphan drug status to sirolimus

Ongoing ALTTO study modified

Takeda initiates phase III program for TAK-875 in Japan

Peregrine Pharmaceuticals completes enrollment in phase II bavituximab trial

EpiCept receives definitive FDA guidance on design of Cepilene registration trial

Taiho sets date for Japanese launch of Zolinza

Sucampo and Numab to collaborate in discovery of high-affinity antibodies

BIBF-1120 obtains Japanese orphan drug status

Roche beings phase I trial of investigational drug for Down syndrome

Janssen Biotech receives complete response letter from FDA regarding sBLA for Simponi

Silence Therapeutics and InteRNA Technologies enter miRNA agreement

Repros Therapeutics to submit IND for vaginal formulation of Proellex

New biomarker to predict clinical outcome of sorafenib-treated hepatocellular carcinoma

Diamyd receives NIH grant to develop NTDDS-based drug candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...